Development of Neuropathology Targeted Treatments in Alzheimer Disease: Madhav R. Thambisetty, MD, PhD
The senior investigator at the National Institute on Aging talked about targeting pathologies in neurodegenerative diseases at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
WATCH TIME: 6 minutes
"I think this is a very exciting time for us in neurodegenerative diseases. As far as Alzheimer disease [AD] is concerned, it looks as if we might for the first time in decades be able to target some of the fundamental pathological changes in the brain in patients with AD. That in itself, is a scientific milestone, it's a landmark and there's a lot of hope around these treatments."
In the field of neurogenerative diseases, particularly Alzheimer disease (AD), researchers have reached a significant scientific milestone in terms of developing treatments with targeted therapies. The development of these therapies potentially may be beneficial for early detection and effective treatments in AD. Although, with the investigation of the new therapies, efficacy and safety are carefully looked at regarding significant adverse events in patients.
Madhav Thambisetty, MD, PhD, a senior investigator at the National Institute on Aging and adjunct professor of neurology at the Johns Hopkins University School of Medicine, will speak at the closing plenary session of AAN which is on the April 27th about targeting pathologies in neurodegenerative disease at 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27, in Boston, Massachusetts.1 In his talk, he will also present the challenges and advancements in the field of neurodegenerative diseases, and the need for greater transparency in clinical trial results.
Thambisetty sat down with NeurologyLive® in an interview at the AAN Annual Meeting to discuss the most promising approaches that currently target the pathologies in neurodegenerative diseases as well as how those differ from previous treatments. He also talked about how researchers balance the need for early intervention in neurodegenerative disease with the potential risks of adverse events with treatments. In addition, Thambisetty shared his insight into the role of interdisciplinary collaborations, such as in the different fields of science and medicine, in developing effective strategies for targeting pathology in neurodegenerative disease.
Click here for more coverage from AAN 2023.
